Shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) fell 8.4% during mid-day trading on Monday . The company traded as low as $7.31 and last traded at $7.45. 1,065,383 shares traded hands during mid-day trading, an increase of 37% from the average session volume of 777,597 shares. The stock had previously closed at $8.13.

A number of research firms have recently issued reports on MRNS. BidaskClub raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 30th. ValuEngine cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Laidlaw began coverage on Marinus Pharmaceuticals in a research report on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $11.00 price objective (up from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.

The company has a market capitalization of $301.41, a P/E ratio of -8.02 and a beta of 2.44.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02.

In other news, major shareholder Bain Capital Life Sciences Inv sold 1,272,547 shares of the stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $7.88, for a total transaction of $10,027,670.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 6.40% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jennison Associates LLC increased its stake in Marinus Pharmaceuticals by 98.0% during the 3rd quarter. Jennison Associates LLC now owns 1,606,733 shares of the biopharmaceutical company’s stock worth $9,432,000 after acquiring an additional 795,068 shares during the period. Bank of New York Mellon Corp bought a new position in Marinus Pharmaceuticals during the 3rd quarter worth $128,000. EAM Investors LLC bought a new position in Marinus Pharmaceuticals during the 3rd quarter worth $554,000. Citadel Advisors LLC increased its stake in Marinus Pharmaceuticals by 327.8% during the 3rd quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 39,371 shares during the period. Finally, Granite Point Capital Management L.P. increased its stake in Marinus Pharmaceuticals by 250.3% during the 3rd quarter. Granite Point Capital Management L.P. now owns 2,684,848 shares of the biopharmaceutical company’s stock worth $15,760,000 after acquiring an additional 1,918,400 shares during the period. Institutional investors own 49.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Marinus Pharmaceuticals (MRNS) Shares Down 8.4%” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/01/08/marinus-pharmaceuticals-mrns-shares-down-8-4.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Stock Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related stocks with our FREE daily email newsletter.